Effect of Complementary Intracoronary Streptokinase Administration Immediately After Primary Percutaneous Coronary Intervention on Microvascular Perfusion and Late Term Infarct Size in Patients With Acute Myocardial Infarction

• Status: Completed
• Trial end date: 2008-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators hypothesized that complementary intracoronary streptokinase administration to primary percutaneous intervention in patients with acute myocardial infarction may provide further improvement in myocardial perfusion by dissolving microvascular thrombus [in situ formed or embolized from proximal site (spontaneous or following PCI)] and fibrin.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Istanbul University
• Treatments: Streptokinase

Criteria

Inclusion criteria:

• Continuous chest pain that lasted > 30 minutes within the preceding 12 hours

• ST-segment elevation of at least 1 mm in 2 contiguous leads on the 12 leads ECG

• Infarct related artery (IRA) occlusion (TIMI grade 0) at the angiography

• Angiographically detected culprit coronary artery lesion deemed suitable for PCI

Exclusion Criteria:

• Contraindications to streptokinase, tirofiban, aspirin, clopidogrel, or heparin

• Culprit lesion in saphenous vein graft

• TIMI grade II-III flow in IRA

• Additional epicardial stenosis in the IRA distal to stented segment (significant or insignificant)

• Presence of left bundle branch block

• History of prior MI

• Mechanical ventilation or inotropic support